JPRN-jRCT2080221037未知Unknown
Post-marketing clinical study of Etoposide Capsule in patients with cervical cancer
ippon Kayaku Co., Ltd.0 个研究点目标入组 40 人开始时间: 2010年3月8日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- Female
入选标准
- •1) Histologically or cytologically or clinically confirmed cervical cancer
- •2) Measurable lesion
- •3) Previously untreated Stage IIIB/IV not amenable to curative surgery or radiation therapy, recurrent or persistent disease
- •4) ECOG PS 0-2
- •5) Body Weight >= 35 kg
- •6) Survival period more than 3 months
- •7) Normal organ function
- •(WBC >= 3,000/mm3, platelets >= 100,000/mm3, hemoglobin >= 9.0g/dL, AST/ALT =< 2 x ULN (patients with liver metastases doesn't have the limitation), total bilirubin =< ULN, serum creatinine =< ULN)
- •8) Written informed consent
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. (JCOG1213,TOPIC-NEC)advanced neuroendocrine carcinoma of the digestive systemJPRN-UMIN000014795Japan Clinical Oncology Group (JCOG)170
进行中（未招募）
1 期
REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerExtended disease Small Cell Lung Cancer (ED-SCLC)MedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003090-42-ITEORTC AISBL/IVZW118
进行中（未招募）
1 期
REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancerExtended disease Small Cell Lung Cancer (ED-SCLC)MedDRA version: 21.1 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003090-42-GBEuropean Organisation for Research and Treatment of Cancer (EORTC)118
进行中（未招募）
不适用
A phase II, multicenter study of etoposide, aracytin, dexamethasone and bortezomib in patients affected by relapsed/refractory multiple myeloma previously treated with thalidomide - NDEUCTR2006-002588-22-ITAZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
进行中（未招募）
不适用
A phase II study of etoposide, oxaliplatin and capecitabine in patients with advanced hepatocellular carcinomaAdvanced Hepatocellular carcinomaEUCTR2005-003187-32-DKDepartment of Oncology, Rigshospitalet39